Recently Viewed
Clear AllBidding Date
06-May-2024 to
08-May-2024
Issue Size
₹1841.76 Cr
Price Band
₹430 to ₹452
Allotment date
09-May-2024
Listing date
13-May-2024
Lot size
33
No. of shares
4,07,46,891
Fresh issue/OFS
₹760 Cr/₹1081.76 Cr
Indegene Ltd was founded as a provider of digital-led commercialization services for the life sciences industry. The company specializes in offering solutions that cover all aspects of commercial, medical, regulatory, and R&D operations for life sciences companies. Its services enable clients to develop products, launch them in the market, and drive sales effectively and efficiently. By combining healthcare domain expertise with fit-for-purpose technology, the company aims to support life sciences enterprises in navigating the complexities of the industry. The company's business is divided in four segments : Enterprise Commercial Solutions, Omnichannel Activation, Enterprise Medical Solutions, and Enterprise Clinical Solutions and Consultancy Services. The company's solutions span different stages of the commercialization lifecycle of drugs and medical devices, catering to both commercial and medical functions of life sciences companies. It operates globally with delivery hubs in North America, Europe, and Asia, offering AI and machine learning-based proprietary platforms to deliver scalable solutions to its clients.
Read our in-depth analysis of the Indegene Ltd IPO Here
Category
Status
QIBs
5.6x
NIIs
18x
Retail
3.8x
Others
--
Total
7.4x
The issue size of Indegene is ₹1,841.76 Cr.
Indegene falls into Biotechnology & R&D industry.
The Indegene IPO will be listed on both NSE and BSE.
The open and close dates for the Indegene are 06-May-2024 & 08-May-2024.
The price band for the Indegene ipo is ₹430 to ₹452
The listing date of Indegene IPO is 13-May-2024.
The purpose of this IPO is to raise fresh capital as well as enable the existing shareholders to sell their stake.
Indegene total subscription ratio is 7.4X.
Key financial of the Indegene are:
| Indegene | FY-24 | FY-23 | FY-22 | FY-21 |
|---|---|---|---|---|
| Revenue (₹ Cr) | 2589.6 | 2306.1 | 1664.61 | 966.3 |
| EBIT (₹ Cr) | 429.3 | 336.1 | 253.47 | 205.1 |
| Proft after Tax (₹ Cr) | 336.7 | 266.1 | 162.82 | 149.4 |
| Debt (₹ Cr) | 403.1 | 394.3 | 18.24 | 24.8 |
| Net Worth (₹ Cr) | 1429.1 | 1063.8 | 763.9 | 333.1 |
| RoE (%) | 23.56 | 25.01 | 21.31 | 44.85 |